What is the right dose? The elusive optimal biologic dose in phase I clinical trials
- PMID: 16943522
- DOI: 10.1200/JCO.2006.07.4658
What is the right dose? The elusive optimal biologic dose in phase I clinical trials
Comment on
-
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources